Key result
GOLDEN study evaluates whether early guideline-directed medical therapy reduces 3-year MACE in ACS patients.
Why the study?
Secondary prevention and long-term adherence to preventive treatment after ACS or coronary revascularisation are often suboptimal, and current strategies are prone to therapeutic inertia and poor patient motivation.
Does a guidelines-based 'first-time-right' pharmacological optimisation strategy initiated during hospitalisation reduce 3-year MACE in patients hospitalised for ACS or coronary revascularisation compared to current practice?
Cohort (n=5,586)
Does a guidelines-based 'first-time-right' pharmacological optimisation strategy initiated during hospitalisation reduce 3-year MACE in patients hospitalised for ACS or coronary revascularisation compared to current practice?
The GOLDEN study is a prospective observational cohort designed to evaluate whether early, in-hospital proactive optimization of guideline-based pharmacotherapy reduces recurrent MACE in patients with ACS or coronary revascularization compared to current practice.
Introduction After an acute coronary syndrome (ACS) or coronary revascularisation, the risk of recurrent vascular events remain substantial. Despite clear guideline recommendations, secondary prevention and long-term adherence to preventive treatment is often suboptimal. Current secondary prevention strategies typically involve initiating a limited number of pharmacologic therapies during hospitalisation, followed by sequential intensification after discharge to achieve individualized guideline-recommended targets. However, this strategy is prone to therapeutic inertia and negatively affects patient motivation and long-term adherence. We hypothesise that a 'first-time-right' strategy, where individualised, guideline-based pharmacological treatment is proactively initiated during hospitalisation, can improve risk factor control and adherence compared to current practice, and thereby reduce major cardiovascular events. Methods and analysis GOLDEN (Guided Optimisation for Long-term Disease rEduction in secoNdary Prevention of cardiovascular disease) is a prospective, temporally controlled observational cohort study aiming to include 5,586 patients hospitalised for ACS or coronary revascularisation. A guidelines-based ‘first-time-right’ pharmacological optimisation strategy will be compared to current practice on the 3-year incidence of cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularisation (4-point MACE). This strategy targets both patients and healthcare professionals and aims to utilise the teachable moment during hospitalisation to optimise pharmacological strategies, apply key behavioural principles to improve adherence, and reframe follow-up from reactive up-titration to proactive de-escalation. A pocket card and online tool will be provided to check applicable guidelines during hospitalisation and formulate follow-up recommendations. An on-site training visit and communication aids are intended to support implementation and promote adherence. Summary This study will evaluate the effects of a ‘first-time-right’ strategy - focused on early in-hospital initiation and optimisation of guideline-based pharmacotherapy after acute coronary syndrome or coronary revascularisation - on the risk of recurrent MACE compared to current practice.
No takes yet. Share an insight, caveat, or question.
Bogaart et al. (2026) conducted a cohort in Acute coronary syndrome or coronary revascularisation (n=5,586). Guidelines-based 'first-time-right' pharmacological optimisation strategy vs. Current practice was evaluated on 3-year incidence of cardiovascular death, myocardial infarction, stroke, or ischemia-driven revascularisation (4-point MACE). The prospective GOLDEN study is designed to evaluate whether a 'first-time-right' pharmacological strategy reduces 3-year 4-point MACE compared to current practice in 5,586 ACS patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: